Meribank Biotech Co., Ltd
4724.TWO
Taipei Exchange10.05
TWD
+0.15
- -
Meribank Biotech Co., Ltd
4724.TWO
(Taipei Exchange)
Recent
price
10.05
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Meribank Biotech Co., Ltd (4724.TWO) researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan; provides handling, testing, frozen storage, and cryopreservation services for umbilical cord blood hematopoietic stem cells, placental umbilical cord mesenchymal stem cells, peripheral blood stem cells, and immune cells; offers prenatal testing, maternal and child health testing, cell viability testing, and stem cell transplantation applications; develops allogeneic umbilical cord mesenchymal stem cell drugs such as UMC119-06-05 for chronic obstructive pulmonary disease, pre-frailty, and frailty in elderly patients, as well as exosome-based products with INCI certification for cosmetics; and operates in the biotechnology sector targeting healthcare providers, hospitals, research institutions, and families for regenerative medicine and cell therapy. Founded in 2013 and headquartered at No. 68, Section 1, Neihu Road, Taipei City, Taiwan, the company employs 142 people and conducts operations primarily in Taiwan with international certifications including U.S. FDA CMC compliance for its production facility. Recent developments include approval from Taiwan's Ministry of Health and Welfare for Phase I/II clinical trials of its stem cell drug UMC119-06-05 in 2025; launch of self-developed exosomes achieving INCI certification; expansion into the health check market through a partnership with Meilien Health Joint Clinic; entry into medical aesthetics via the EX-MU brand targeting clinics with exosome products; and a NT$647 million acquisition of 99% of Yutuo Management Consulting (Zhubei Yutuo) via stock swap to integrate upstream and downstream maternal-infant services, alongside growth in its management consulting department contributing NT$88.24 million in 2024 sales.